Recent research has also found that selective COX-2 inhibitors can enhance the sensitivity of tumor cells to many kinds of chemotherapeutic drugs, thus reducing the IC50 of chemotherapeutic drugs by nearly 70% [19]. This evidence concerns the gene PTGS2 and neoplasm.